DK3512857T3 - Spiro-bicykliske inhibitorer af menin-mll-interaktion - Google Patents

Spiro-bicykliske inhibitorer af menin-mll-interaktion Download PDF

Info

Publication number
DK3512857T3
DK3512857T3 DK17768428.9T DK17768428T DK3512857T3 DK 3512857 T3 DK3512857 T3 DK 3512857T3 DK 17768428 T DK17768428 T DK 17768428T DK 3512857 T3 DK3512857 T3 DK 3512857T3
Authority
DK
Denmark
Prior art keywords
menin
spiro
mll interaction
bicyclic inhibitors
bicyclic
Prior art date
Application number
DK17768428.9T
Other languages
English (en)
Inventor
Patrick René Angibaud
Vineet Pande
Barbara Herkert
Daniel Jason Krosky
Olivier Alexis Georges Querolle
Aaron Nathaniel Patrick
Isabelle Noëlle Constance Pilatte
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2017/073004 external-priority patent/WO2018050686A1/en
Application granted granted Critical
Publication of DK3512857T3 publication Critical patent/DK3512857T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK17768428.9T 2016-09-14 2017-09-13 Spiro-bicykliske inhibitorer af menin-mll-interaktion DK3512857T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394295P 2016-09-14 2016-09-14
EP16192431 2016-10-05
PCT/EP2017/073004 WO2018050686A1 (en) 2016-09-14 2017-09-13 Spiro bicyclic inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
DK3512857T3 true DK3512857T3 (da) 2021-05-10

Family

ID=59895299

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17768428.9T DK3512857T3 (da) 2016-09-14 2017-09-13 Spiro-bicykliske inhibitorer af menin-mll-interaktion

Country Status (15)

Country Link
US (1) US11220517B2 (da)
EP (1) EP3512857B1 (da)
JP (1) JP6975791B2 (da)
KR (1) KR102493644B1 (da)
CN (1) CN109689663B (da)
AU (1) AU2017326487B2 (da)
BR (1) BR112019004691A2 (da)
DK (1) DK3512857T3 (da)
ES (1) ES2872003T3 (da)
HR (1) HRP20210514T1 (da)
HU (1) HUE053907T2 (da)
IL (1) IL265233B (da)
LT (1) LT3512857T (da)
MX (1) MX392051B (da)
SI (1) SI3512857T1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3033020A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
CN110248946B (zh) 2016-12-15 2023-05-23 詹森药业有限公司 Menin-MLL相互作用的氮杂环庚烷抑制剂
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7618567B2 (ja) 2019-09-27 2025-01-21 住友ファーマ株式会社 架橋型光学活性2級アミン誘導体
CN112812584A (zh) * 2019-11-16 2021-05-18 复旦大学 一种含氮杂环丁烷螺环结构的荧光染料及其制备方法和应用
TW202525813A (zh) * 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
WO2023244870A1 (en) * 2022-06-17 2023-12-21 INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER Compositions and methods for control of transient site-specific copy gains, genomic insertions, and rearrangements associated with mixed lineage leukemia
CN121969626A (zh) * 2023-09-27 2026-05-01 苏州必扬医药科技有限公司 一种Menin-MLL相互作用抑制剂及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
JP2005527502A (ja) 2002-02-19 2005-09-15 シーブイ・セラピューティクス・インコーポレイテッド A1アデノシン受容体の部分的および全アゴニスト
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
JP4660199B2 (ja) 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換1−ピペリジン−4−イル−4−アゼチジン−3−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
WO2005110410A2 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
EP1856128A4 (en) 2005-01-19 2009-12-23 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
WO2010041366A1 (ja) 2008-10-06 2010-04-15 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及び記録媒体
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
WO2011020567A1 (de) * 2009-08-20 2011-02-24 Bayer Cropscience Ag 3-triazolylphenyl-substituierte sulfid-derivate als akarizide und insektizide
CN102984941B (zh) 2009-09-04 2016-08-17 密执安大学评议会 用于治疗白血病的组合物和方法
US9586961B2 (en) * 2010-07-09 2017-03-07 Leo Pharma A/S Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
EP2646455A4 (en) 2010-12-03 2014-04-02 Epizyme Inc Modulators of histone methyltransferase, and methods of use thereof
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
CN103228195B (zh) 2011-08-01 2016-01-20 奥林巴斯株式会社 插入部形状估计装置
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
BR112015011148A8 (pt) * 2012-11-16 2019-10-01 Merck Sharp & Dohme composto, composição farmacêutica, e combinação
DK2935222T3 (da) 2012-12-21 2019-01-07 Epizyme Inc Prmt5-inhibitorer og anvendelser deraf
CA2894126A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
WO2014164543A1 (en) * 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015171738A2 (en) * 2014-05-06 2015-11-12 The Procter & Gamble Company Fragrance compositions
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
US20170198006A1 (en) 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
MX2017010844A (es) 2015-02-24 2017-12-07 Pfizer Derivados de nucleosidos sustituidos utiles como agentes anticancerosos.
TWI703150B (zh) 2015-06-04 2020-09-01 美商庫拉腫瘤技術股份有限公司 用於抑制menin及mll蛋白之交互作用的方法及組合物
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
TWI870767B (zh) 2015-08-26 2025-01-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
JP6991585B2 (ja) 2016-05-02 2022-01-12 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン メニン阻害剤としてのピペリジン
WO2017207387A1 (en) * 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
WO2017214367A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) * 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
WO2018047598A1 (ja) 2016-09-06 2018-03-15 株式会社スリーボンド 熱硬化型導電性接着剤
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
EP3512857B1 (en) 2016-09-14 2021-02-24 Janssen Pharmaceutica NV Spiro bicyclic inhibitors of menin-mll interaction
CA3033020A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
AU2017326006B2 (en) 2016-09-16 2021-10-28 Vitae Pharmaceuticals, LLC. Inhibitors of the menin-MLL interaction
WO2018109088A1 (en) 2016-12-15 2018-06-21 Janssen Pharmaceutica Nv Azepane inhibitors of menin-mll interaction
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma

Also Published As

Publication number Publication date
IL265233B (en) 2021-06-30
US20190211036A1 (en) 2019-07-11
ES2872003T3 (es) 2021-11-02
EP3512857B1 (en) 2021-02-24
JP6975791B2 (ja) 2021-12-01
KR20190045242A (ko) 2019-05-02
HUE053907T2 (hu) 2021-07-28
CN109689663A (zh) 2019-04-26
JP2019532100A (ja) 2019-11-07
CN109689663B (zh) 2023-04-14
SI3512857T1 (sl) 2021-07-30
BR112019004691A2 (pt) 2019-06-25
US11220517B2 (en) 2022-01-11
AU2017326487B2 (en) 2021-08-05
IL265233A (en) 2019-05-30
AU2017326487A1 (en) 2019-02-28
EP3512857A1 (en) 2019-07-24
HRP20210514T1 (hr) 2021-05-14
LT3512857T (lt) 2021-04-12
MX2019002962A (es) 2019-07-04
KR102493644B1 (ko) 2023-01-30
MX392051B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
IL263586B (en) Inhibitors of the menin-mll interaction
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3512857T3 (da) Spiro-bicykliske inhibitorer af menin-mll-interaktion
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3377059T3 (da) Hæmmere af cxcr2
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3371171T3 (da) Inhibitorer af RET
DK3509581T3 (da) Formuleringer af (r)-2-amino-3-phenylpropylcarbamat
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3442972T3 (da) Bromdomænehæmmere
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3317400T3 (da) Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter
DK3466432T3 (da) Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3261726T3 (da) Sammensætning til behandling af acne
DK3551625T3 (da) Heterocykliske inhibitorer af mct4
DK3341379T3 (da) EZH2-hæmmere
DK3562487T3 (da) Metalloenzyminhibitorforbindelser
DK3474822T3 (da) Formuleringer af brincidofovir
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
DK3307267T3 (da) Behandling af multipel sklerose